Literature DB >> 25392744

Molecular Strategies of Deoxynucleotide Triphosphate Supply Inhibition Used in the Treatment of Gynecologic Malignancies.

Charles A Kunos1, Tomas Radivoyevitch2.   

Abstract

Chemotherapies targeting deoxynucleotide triphosphate synthesis are of high medical interest in the treatment of gynecologic malignancies. In this article, we focus on targeted inhibitors of ribonucleotide reductase, an enzyme in charge of ribonucleotide reduction to their corresponding deoxyribonucleotide to be used as the building blocks of DNA. We also discuss human clinical trials have utilized ribonucleotide reductase subunit-specific inhibitors, particularly trials for women with cervical cancer.

Entities:  

Year:  2011        PMID: 25392744      PMCID: PMC4226428          DOI: 10.4172/2161-0932.s4-001

Source DB:  PubMed          Journal:  Gynecol Obstet (Sunnyvale)


  48 in total

1.  Are we making progress in curing advanced cervical cancer?

Authors:  Gillian Thomas
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

2.  Controlled protein degradation regulates ribonucleotide reductase activity in proliferating mammalian cells during the normal cell cycle and in response to DNA damage and replication blocks.

Authors:  A Chabes; L Thelander
Journal:  J Biol Chem       Date:  2000-06-09       Impact factor: 5.157

3.  Expression of ribonucleotide reductase after ionizing radiation in human cervical carcinoma cells.

Authors:  M L Kuo; T J Kinsella
Journal:  Cancer Res       Date:  1998-05-15       Impact factor: 12.701

4.  Nucleotide sequence and comparative analysis of the human papillomavirus type 18 genome. Phylogeny of papillomaviruses and repeated structure of the E6 and E7 gene products.

Authors:  S T Cole; O Danos
Journal:  J Mol Biol       Date:  1987-02-20       Impact factor: 5.469

5.  Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers.

Authors:  Charles A Kunos; Tomas Radivoyevitch; John Pink; Song-Mao Chiu; Tammy Stefan; James Jacobberger; Timothy J Kinsella
Journal:  Radiat Res       Date:  2010-09-10       Impact factor: 2.841

6.  Radiosensitization of human cervical cancer cells by inhibiting ribonucleotide reductase: enhanced radiation response at low-dose rates.

Authors:  Charles A Kunos; Valdir C Colussi; John Pink; Tomas Radivoyevitch; Nancy L Oleinick
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-04       Impact factor: 7.038

7.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.

Authors:  Mark E Davis; Jonathan E Zuckerman; Chung Hang J Choi; David Seligson; Anthony Tolcher; Christopher A Alabi; Yun Yen; Jeremy D Heidel; Antoni Ribas
Journal:  Nature       Date:  2010-03-21       Impact factor: 49.962

8.  Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.

Authors:  Patricia J Eifel; Kathryn Winter; Mitchell Morris; Charles Levenback; Perry W Grigsby; Jay Cooper; Marvin Rotman; David Gershenson; David G Mutch
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

9.  A phase I study of gemcitabine followed by cisplatin concurrent with whole pelvic radiation therapy in locally advanced cervical cancer: a Gynecologic Oncology Group study.

Authors:  Peter G Rose; Koen Degeest; Scott McMeekin; Nancy Fusco
Journal:  Gynecol Oncol       Date:  2007-08-03       Impact factor: 5.482

10.  Protein domains governing interactions between E2F, the retinoblastoma gene product, and human papillomavirus type 16 E7 protein.

Authors:  P S Huang; D R Patrick; G Edwards; P J Goodhart; H E Huber; L Miles; V M Garsky; A Oliff; D C Heimbrook
Journal:  Mol Cell Biol       Date:  1993-02       Impact factor: 4.272

View more
  4 in total

1.  Randomized Phase II Trial of Triapine-Cisplatin-Radiotherapy for Locally Advanced Stage Uterine Cervix or Vaginal Cancers.

Authors:  Charles A Kunos; Stephen J Andrews; Kathleen N Moore; Hye Sook Chon; S Percy Ivy
Journal:  Front Oncol       Date:  2019-10-15       Impact factor: 6.244

2.  Inhibition of Poly(ADP-Ribose) Polymerase Enhances Radiochemosensitivity in Cancers Proficient in DNA Double-Strand Break Repair.

Authors:  Lauren Shunkwiler; Gina Ferris; Charles Kunos
Journal:  Int J Mol Sci       Date:  2013-02-08       Impact factor: 5.923

3.  Long-Term Disease Control with Triapine-Based Radiochemotherapy for Patients with Stage IB2-IIIB Cervical Cancer.

Authors:  Charles A Kunos; Tracy M Sherertz
Journal:  Front Oncol       Date:  2014-07-24       Impact factor: 6.244

4.  Triapine Radiochemotherapy in Advanced Stage Cervical Cancer.

Authors:  Charles A Kunos; S Percy Ivy
Journal:  Front Oncol       Date:  2018-05-07       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.